Digital health company Hims & Hers Health Inc. reported strong fourth-quarter revenue growth, surpassing analyst expectations. However, the company issued guidance for the first quarter of 2024 that fell below market projections, generating a mixed reaction among investors and highlighting near-term challenges in the telehealth sector. Fourth-quarter revenue reached $247 million, representing year-over-year growth of over 40%. This growth was driven by a subscriber base exceeding one million users, solidifying its direct-to-consumer subscription model for health and wellness treatments.
The context for these results lies within a digital health market that experienced a significant boom during the pandemic but now faces normalized demand and increased competition. Hims & Hers, known for offering discreet, online treatments for hair loss, sexual health, skincare, and mental health, has successfully diversified its portfolio. "Our fourth-quarter results reflect the strength of our business model and the growing acceptance of digital health as a fundamental solution," stated Andrew Dudum, CEO of the company, in the earnings release.
Despite the strong performance in the last quarter of 2023, guidance for the first quarter of 2024 projects revenue between $255 million and $265 million, below the analyst consensus of approximately $268 million. This more conservative outlook is attributed to typical first-quarter seasonal factors and ongoing investments in marketing and category expansion. The company maintained its optimistic full-year 2024 outlook, anticipating sustained growth, but the caution for the start of the year resonates in an economic environment where consumer spending on discretionary health services may be pressured.
The impact of this announcement was immediate in the markets, with the company's stock experiencing volatility in after-hours trading following the earnings release. Analysts note that while the near-term guidance is soft, Hims & Hers's long-term fundamentals remain solid due to its scalability, improved margins, and the secular trend toward the digitization of healthcare. The company also reported progress toward profitability, significantly reducing its net losses compared to the previous year.
In conclusion, Hims & Hers Health demonstrates robust growth and increasing adoption of its platforms, validating its business model. However, the conservative guidance for the upcoming quarter serves as a reminder that the telehealth journey, while promising, is not without bumps. The company's performance throughout 2024 will be key to assessing whether it can maintain its momentum in an evolving competitive and economic landscape, balancing growth investment with the pursuit of profitability.